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Background: Increased epicardial adipose tissue thickness and plasma homocysteine levels are associated with
Metabolic Syndrome (MS) and coronary artery disease. The majority of patients with MS have subclinical or manifest
coronary artery disease. The aim of this study was to evaluate the relationship between MS and plasma
homocysteine levels and epicardial adipose tissue thickness in subjects without epicardial coronary artery disease.
Methods: Patients who underwent coronary angiography due to angina or equivocal symptoms and/or abnormal
stress test results and were found to have normal coronary arteries were evaluated for the presence of MS. The
study group comprised 75 patients with normal coronary arteries and MS, and the control group included 75
age-gender matched subjects without coronary artery disease or MS.
Results: Epicardial adipose tissue thickness (5.8 ± 1.9 mm vs. 4.3 ± 1.6 mm, p <0.001) and plasma homocysteine
levels (21.6 ± 6.1 μmol/L vs. 15.1 ± 5.8 μmol/L, p <0.001) were significantly higher in the MS group. Body mass index,
triglyceride level, weight, age and waist circumference were positively and HDL cholesterol level were negatively
correlated with both epicardial adipose tissue thickness and plasma homocysteine level. Epicardial adipose tissue
thickness had the strongest correlation with plasma homocysteine level (r = 0.584, p < 0.001). For each 1 mm
increase in epicardial adipose tissue thickness, an increase of 3.51 μmol/L (95% CI: 2.24-4.79) in plasma homocysteine
level was expected.
Conclusions: We observed a close relationship between MS and epicardial adipose tissue thickness and plasma
homocysteine levels, even in the absence of overt coronary artery disease.
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Metabolic syndrome (MS) is a combination of disorders
that increase the risk of cardiovascular disease and dia-
betes, including abdominal obesity, raised fasting plasma
glucose, atherogenic dyslipidemia and high blood pressure
[1]. Approximately 20 to 25 percent of the global popula-
tion has MS, which is associated with a twofold increase
in cardiovascular mortality and a threefold increase in the
risk of myocardial infarction or stroke. In addition, the risk
of developing type 2 diabetes is five times higher in people* Correspondence: serhatbalcioglu@gmail.com
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unless otherwise stated.with MS [2]. Abdominal obesity and insulin resistance
play a key role in the development of MS and data sug-
gests that prothrombotic and proinflammatory states are
also involved [3].
Homocysteine, a sulfur-containing amino acid, is pro-
duced through the metabolism of methionine. Elevated
plasma homocysteine is associated with cardiovascular
disease and stroke [4]. Studies have demonstrated that
homocysteine induces endothelial cell injury and impairs
endothelium-dependent vasodilation by decreasing the
generation of nitric oxide and increasing the inactivation
of nitric oxide [5-7]. The relationship between increased
plasma homocysteine level and insulin resistance/hyper-
insulinemia has been previously demonstrated [8,9]. Inal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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been detected in patients with MS and clinically manifest
atherosclerotic vascular disease [10].
Epicardial adipose tissue (EAT), deriving from the same
embryological origin as mesenteric and omental fat, is de-
posited around the heart, particularly around the coronary
vessels [11]. EAT may influence coronary atherosclerosis
and myocardial function due to the lack of a fibrous barrier
blocking diffusion of free fatty acids and adipokines from the
EAT to the underlying vessels and myocardium [11]. A re-
cent meta-analysis demonstrated significantly higher echo-
cardiographic EAT thickness in patients with MS [12]. EAT
thickness is also related to epicardial obstructive coronary ar-
tery disease, myocardial ischemia, major adverse cardiac
events and subclinical coronary artery disease [13-16].
It is known that the majority of patients with MS have
subclinical or manifest coronary artery disease. As both
plasma homocysteine and EAT are associated with coron-
ary artery disease, the presence of concomitant coronary
artery disease may influence the level of plasma homocyst-
eine and EAT thickness in patients with MS. Therefore,
the aim of this study was to evaluate the relation between
MS and plasma homocysteine level and EAT thickness in
subjects without epicardial coronary artery disease.
Methods
Patients who underwent coronary angiography due to an-
gina or equivocal symptoms and/or abnormal stress tests
and who were found to have normal coronary arteries
were evaluated for the presence of MS according to Inter-
national Diabetes Federation criteria [17].
The study group comprised of 75 patients without cor-
onary artery disease diagnosed with MS and the control
group included 75 age-gender matched subjects without
coronary artery disease or MS. The anthropometric char-
acteristics of the control group were similar to those of
the study group. All subjects in the control group had a
risk factor of 0 or 1 for MS, mostly enlarged waist circum-
ference (Table 1). The International Diabetes Federation
defines MS as central obesity plus any two of the following
four factors: raised fasting plasma glucose (≥100 mg/dL)
or treatment of previously diagnosed type 2 diabetes,
raised blood pressure (systolic blood pressure ≥130 or dia-
stolic blood pressure ≥85 mmHg) or treatment of previously
diagnosed hypertension, raised triglycerides (≥150 mg/dl),
and reduced HDL cholesterol (<40 mg/dL in males, <50 mg/
dL in females). Central obesity was accepted as a waist cir-
cumference of ≥94 cm in males and ≥80 cm in females in
our study group [17]. Subjects with coronary artery disease,
diabetes mellitus, folic acid deficiency, malabsorption syn-
dromes, hypo-hyperthyroidism or chronic systemic illness
were excluded. Patients using drugs that can affect the level
of plasma homocysteine and those with a poor acoustic win-
dow were also excluded. The study was performed inaccordance with the principles stated in the Declaration of
Helsinki and was approved by the Medical Ethics Committee
of Başkent University. All subjects gave informed consent
prior to enrollment.
Venous blood samples were collected after fasting for a
minimum of twelve hours. Thyroid function, plasma glucose,
total cholesterol, HDL cholesterol, LDL cholesterol, triglycer-
ide, folic acid and homocysteine were measured. Plasma
homocysteine assay was performed using the AxSYM im-
munoassay according to the manufacturer’s instructions.
Plasma homocysteine levels between 3.36 and 20.44 μmol/L
in men and 5.9 and 16 μmol/L in women were considered
normal according to the kit used in the study.
Anthropometric measurements were obtained by
well-trained medical staff using the same methods and
instruments for all participant. Waist circumference
was measured at the midpoint between the lower rib
margin and the iliac crest.
Blood pressure values were obtained in the echocardiog-
raphy room using the traditional auscultatory method with
a sphygmomanometer. Patients were advised to refrain
from smoking, consuming coffee or tea and physical exer-
cise for 30 minutes and were seated for rest for five minutes
prior to the measurement. Three separate measurements
were averaged to determine office blood pressure.
Subjects underwent transthoracic echocardiography in
the left lateral decubitus position using a General Electric
Vivid e (General Electric HealthCare Ultrasound Cardi-
ology, Horton, Norway) and a 3.5 MHz transducer ac-
cording to the guidelines of the American Society of
Echocardiography by the same cardiologist specialized
in echocardiography [18]. EAT thickness was measured
on the free wall of the right ventricle at the end-diastole
using both parasternal long and short axis views on M-
mode echocardiography in three cardiac cycles, as de-
scribed by Iacobellis [19]. Maximum values at any site
were measured and the average value was used for stat-
istical analyses. Intraobserver agreement was tested
using repeated measures and no significant differences
were seen for randomly selected subjects (intraclass cor-
relation analysis was used and the strength of the con-
cordance was 0.94).
Statistical methods
The Statistical Program for Social Sciences (SPSS for win-
dows 15, Inc., Chicago, IL, USA) was used for all statistical
calculations. Continuous variables are given as mean ±
standard deviation; categorical variables are defined as
numbers and percentages. Data were tested for normal
distribution using the Kolmogorov-Smirnov test. Continu-
ous variables were compared using the Student t test and
Mann Whitney U test where appropriate. The chi-square
test was used for comparison of the categorical variables
between the two groups. Univariate correlation analysis
Table 1 Comparison of characteristics, blood samples and echocardiographic findings
Metabolic syndrome group (n = 75) Control group (n = 75) P value
Age, years 59.6 ± 14.0 57.0 ± 15.2 NS
Gender, male/female, numbers (%) 28/47 (37.3/62.7) 32/43 (42.7/57.3) NS
Hypertension, numbers (%) 22 (29.3) 14 (18.7) NS
Height, cm 165.3 ± 8.5 164.9 ± 6.8 NS
Weight, kg 79.2 ± 10.3 73.5 ± 11.1 0.001
Body mass index, kg/m2 29.0 ± 3.6 27.1 ± 3.8 <0.001
Waist circumference, cm 93.8 ± 7.9 89.0 ± 9.6 <0.001
Central obesity criterion, numbers (%) 75 (100) 50 (66.7) <0.001
Fasting plasma glucose, mg/dL 101.5 ± 12.1 99.5 ± 11.1 NS
Total cholesterol, mg/dL 191.4 ± 47.0 184.1 ± 43.5 NS
HDL cholesterol, mg/dL 40.4 ± 8.1 48.2 ± 11.1 <0.001
LDL cholesterol, mg/dL 116.5 ± 41.1 112.2 ± 38.1 NS
Trygliceride, mg/dL 172.4 ± 63.2 119.0 ± 53.0 <0.001
Systolic blood pressure, mmHg 128.5 ± 8.7 124.0 ± 10.7 0.001
Diastolic blood pressure, mmHg 80.9 ± 8.5 78.5 ± 7.1 0.021
Smokers, numbers (%) 18 (24) 23 (30.7) NS
EAT thickness, mm 5.8 ± 1.9 4.3 ± 1.6 <0.001
Plasma homocysteine level, μmol/L 21.6 ± 6.1 15.1 ± 5.8 <0.001
Ventricular septum thickness, mm 11.5 ± 1.9 11.3 ± 1.6 NS
Posterior wall thickness, mm 10.6 ± 1.7 10.6 ± 1.5 NS
Left ventricular mass, g 185.4 ± 58.0 174.5 ± 46.9 NS
Left atrial diameter, mm 35.4 ± 5.2 35.3 ± 4.4 NS
Data are expressed as mean ± standard deviation or numbers (percentages). EAT = epicardial adipose tissue, NS = not significant.
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that potentially affected EAT thickness and plasma homo-
cysteine level. Variables with a p value of <0.05 in univariate
correlation analysis were included in a multivariate stepwise
linear regression analysis model in order to assess the inde-
pendent determinants of EAT thickness and plasma homo-
cysteine level. All tests of significance were two-tailed.
Statistical significance was defined as p <0.05.
Results
Study population
General characteristics of the study population are pre-
sented in Table 1. As expected, weight, waist circumfer-
ence, body mass index and systolic and diastolic blood
pressure were higher in the MS group. Height was not dif-
ferent between groups. The study group had higher
plasma triglyceride levels and lower HDL levels. Plasma
fasting glucose, total cholesterol and LDL cholesterol were
similar in both groups.
EAT thickness
EAT thickness was significantly higher in patients with MS
(Table 1) and was similar between gender groups (5.3 ±
1.9 mm in men, 4.9 ± 1.9 mm in women, p = 0.357). In theunivariate correlation analysis, body mass index, triglyceride
level, weight, age and waist circumference were correlated
positively whereas HDL cholesterol level was correlated
negatively with EAT thickness. However, plasma homocyst-
eine levels had the strongest correlation with EAT thickness
(Table 2). Moreover, EAT thickness was found to be related
to some echocardiographic measures, including ventricular
septum thickness, posterior wall thickness, left ventricular
mass and left atrial diameter (Table 2).Homocysteine concentrations
Plasma homocysteine levels were higher in patients with
MS (21.6 ± 6.1 μmol/L vs. 15.1 ± 5.8 μmol/L, p < 0.001)
and hypertension (21.7 ± 7.3 μmol/L vs. 17.3 ± 6.3 μmol/L,
p = 0.002). There was no significant difference between
groups according to gender (19.2 ± 6.9 μmol/L in men,
17.8 ± 6.7 μmol/L in women, p = 0.195). EAT thickness,
HDL cholesterol (reversely), systolic blood pressure, trigly-
ceride level, diastolic blood pressure, body mass index,
weight, age and weight circumference were significantly
correlated with plasma homocysteine levels (Table 2). No
association was found between homocysteine levels and
echocardiographic measurements.
Table 2 Results of univariate correlation analysis for epicardial adipose tissue thickness and homocysteine levels
Variables EAT thickness Plasma homocysteine level
r P value r P value
Plasma homocysteine level 0.584 <0.001 - -
EAT thickness - - 0.584 <0.001
Body mass index 0.423 <0.001 0.261 0.001
Triglyceride level 0.383 <0.001 0.335 <0.001
Weight 0.354 <0.001 0.243 0.003
Age 0.297 <0.001 0.206 0.012
Waist circumference 0.280 0.001 0.161 0.049
HDL cholesterol level −0.218 0.007 −0.394 <0.001
Systolic blood pressure 0.149 NS 0.352 <0.001
Diastolic blood pressure 0.076 NS 0.266 0.001
Fasting plasma glucose 0.139 NS 0.039 NS
Ventricular septum thickness 0.190 0.020 0.139 NS
Posterior wall thickness 0.249 0.002 0.156 NS
Left ventricular mass 0.219 0.007 0.126 NS
Left atrial diameter 0.267 0.001 0.148 NS
EAT = epicardial adipose tissue, NS = not significant.
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The multivariate stepwise linear regression analysis revealed
that plasma triglyceride level, age, body mass index, left
atrial diameter and diagnosis of MS were the independent
determinants of EAT thickness (Table 3). The independent
determinants of plasma homocysteine level were systolic
blood pressure, plasma triglyceride and HDL cholesterol
levels and the diagnosis of MS (Table 4). For each 1 mm in-
crease in thickness of EAT, a 3.51 μmol/L (95%CI: 2.24-
4.79) increase in plasma homocysteine level was expected.Discussion
In this study, we observed that plasma homocysteine levels
and EAT thickness were increased in patients with MS. MS
is a combination of several disorders, in which insulinTable 3 Multivariate stepwise linear regression analysis for ep
B SRC t
Age 0.029 0.229 3.578
Triglyceride level 0.008 0.262 3.737
Body mass index 0.156 0.315 4.774
Diagnosis of MS 0.741 0.197 2.734
IVS thickness −0.028 −0.026 −0.186
PW thickness 0.226 0.193 1.313
LVM −0.006 −0.165 −1.181
Left atrial diameter 0.088 0.222 2.724
Dependent variable: Epicardial adipose tissue thickness, B = coefficient of regression
mass, MS =Metabolic Syndrome, PW = posterior wall, SRC = standardized regressionresistance and prothrombotic and proinflammatory states
are common pathophysiological mechanisms [1].
Many previous studies and meta-analyses have demon-
strated that EAT thickness and plasma homocysteine were
increased in patients with MS and/or coronary artery dis-
ease [4,12,20,21]. Ding et al. showed that an increased
quantity of EAT is associated with incident coronary artery
disease and major adverse cardiac events independent of
conventional risk factors [22]. There have been several
meta-analyses investigating the association between homo-
cysteine and coronary artery disease. One meta-analysis,
including 72 case–control studies investigating the effect of
methylentetrahydrofolate reductase gene mutation and 20
prospective studies evaluating the relation of serum homo-
cysteine with coronary artery disease, demonstrated an
odds ratio of 1.42 (95% CI 1.11-1.84) in case-controls andicardial adipose tissue
P value 95% CI for B
Lower bound Upper bound
<0.001 0.013 0.046
<0.001 0.004 0.012
<0.001 0.092 0.221
0.007 0.205 1.278
0.853 −0.324 0.269
0.191 −0.114 0.566
0.240 −0.016 0.004
0.007 0.024 0.151
, CI = confidence interval, IVS = interventricular septum, LVM = left ventricular
coefficient (r2 = 0.405).
Table 4 Multivariate stepwise linear regression analysis for plasma homocysteine level
Variable B SRC t P value 95% CI for B
Lower bound Upper bound
HDL cholesterol level −0.151 −0.232 −3.299 0.001 −0.241 −0.060
Diagnosis of MS 3.229 0.239 3.028 0.003 1.121 5.337
Systolic blood pressure 0.130 0.191 2.651 0.009 0.033 0.227
Triglyceride level 0.015 0.144 2.009 0.046 0.000 0.030
Dependent variable: Plasma homocysteine level, B = coefficient of regression, CI = confidence interval, EAT = epicardial adipose tissue, MS =Metabolic Syndrome,
SRC = standardized regression coefficient (r2 = 0.404).
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crease of 5 μmol/L in plasma homocysteine [23]. Similarly,
a homocysteine level 25% higher than usual had an odds
ratio of 1.12 (95% CI 1.04-1.20) in a meta-analysis involv-
ing 5073 cardiac events [4].
The relationship between EAT and MS is also well
known. In a recent meta-analysis consisting of 2027
subjects of whom 1030 had MS, EAT thickness was sig-
nificantly higher in patients with MS (standardized differ-
ence in means 1.15 mm, 95% CI 0.78 to 1.53, p =0.0001)
[12]. Cut-off points for EAT thickness have been proposed
to diagnose MS. Okyay et al. reported that EAT thickness
of >4.35 mm indicated MS according to International Dia-
betes Federation criteria [21]. Although there is conflicting
data regarding the association between plasma homocys-
tene level and MS, several studies support this relationship
[8-10,24,25]. In addition, in patients with coronary artery
disease, plasma homocysteine levels were found to be
higher in subjects with MS than in those without [10].
This association between homocysteine level and MS was
also observed in patients with prior myocardial infarction
[26]. However, Hajer et al. reported that while not related
to increased cardiovascular risk, plasma homocystein
levels were high in patients with atherosclerotic vascular
disease and MS [10].
When all of these complex and entwined relations are
considered, the absence of epicardial coronary artery
disease in our study population distinguishes as the
presence of concomitant coronary artery disease may
influence the amount of plasma homocysteine level and
EAT thickness. Even so, we detected significantly higher
plasma homocysteine and EAT thickness in subjects
with MS compared with control subjects.
EAT has various endocrine and inflammatory func-
tions and produce mediators such as interleukin-6,
interleukin-1b, tumor necrosis factor-α and monocyte
chemotactic protein-1, which can cause endothelial dys-
function [27]. Unlike white adipose tissue, brown fat ex-
presses adiponectin, which has a protective effect on
endothelial function [28,29]. Several studies have shown
an inverse association between brown adipose tissue and
obesity, impaired glucose tolerance, and type 2 diabetes
mellitus [29]. Accordingly, the dysregulated production ofadiponectin may contribute to endothelial dysfunction in
subjects with MS [30].
Consistent with our results, a previous study on 68
women with chest pain and angiographically normal cor-
onary arteries revealed that EAT thickness related to
microvascular dysfunction, an indicator of endothelial
dysfunction [31]. Even though the authors did not meas-
ure plasma homocysteine, we may speculate that this ef-
fect is in part due to homocysteine mediated endothelial
dysfunction by both inducing endothelial cell injury and
impairing nitric oxide levels [5-7].
Results of our study may be interpreted as showing that
plasma homocysteine and EAT thickness begin to increase
before angiographically detectable coronary artery disease
in patients with MS, which represent a population at high
risk for coronary artery disease. Moreover, as both EAT
and homocysteine lead to endothelial dysfunction, a key
event in the development of atherosclerosis predating clin-
ically obvious vascular disease [32], these two factors may
contribute to the initiation, progression and acceleration
of coronary artery disease in patients with MS. For this rea-
son, plasma homocysteine level and EAT thickness may be
used as additional and easy diagnostic tools for the pres-
ence of endothelial dysfunction and the necessity for
follow-up for possible future overt coronary artery disease.
In a recent study, Iacobellis et al. demonstrated that EAT
thickness was found to be a good predictor of steatosis of
non-cardiac organs such as the liver [33]. We previously
showed that a relationship exists between nonalcoholic fatty
liver disease and the presence of coronary artery disease
[34]. These findings may also support the role of EAT on
the process of coronary artery disease.
EAT volume was associated with MS and cardiometabolic
risk factors, including plasma homocysteine, in patients
with rheumatoid arthritis [35]. Our study also confirms the
association between plasma homocysteine and EAT thick-
ness in patients with MS. Moreover, the correlation be-
tween EAT thickness and left ventricular mass in our study
is consistent with previous studies [36,37].
Study limitations
The use of conventional coronary angiography for diag-
nosis of normal coronary arteries may be considered a
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onary artery disease (plaque formation) and better deter-
mination of the atherosclerotic process may be possible
if coronary angiography had been supported with intra-
vascular ultrasound. In addition, we did not measure
additional indicators of atherosclerosis, such as carotid
intima-media thickness or ankle brachial indices. Lastly,
we do not have long-term follow-up data on cardiovas-
cular events.
Conclusions
Our study demonstrated the close relationships between
MS and EAT thickness and plasma homocysteine level in
the absence of overt coronary artery disease. Although we
cannot reveal the underlying pathological process of these
findings, we think that increased EAT and homocysteine
may constitute a higher cardiovascular risk in patients
with MS and can be used to help diagnosis of endothelial
dysfunction in patients complaining of chest pain with
normal coronary arteries.
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